Targeting inflammasomes in rheumatic diseases

Nature Reviews Rheumatology

Volumn 9, Issue 7, 2013, Pages 391-399

  So, Alexander ^a   Ives, Annette ^a   Joosten, Leo A B ^b   Busso, Nathalie ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SENSING RECEPTOR; CALGRANULIN A; CALGRANULIN B; CASPASE RECRUITMENT DOMAIN SIGNALING PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CRYOPYRIN; GUANYLATE BINDING PROTEIN 5; INFLAMMASOME; INTERLEUKIN 1BETA CONVERTING ENZYME; MEMBRANE PROTEIN; MEVALONATE KINASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PHOSPHOLIPASE C; PROTEIN KINASE R; PURINERGIC P2X7 RECEPTOR; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; AUTOPHAGY; BINDING AFFINITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG TARGETING; ENZYME ACTIVATION; GOUT; HUMAN; IMMUNE RESPONSE; INFECTIOUS ARTHRITIS; INNATE IMMUNITY; OSTEOARTHRITIS; OXIDATION REDUCTION POTENTIAL; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

CARRIER PROTEINS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; INFLAMMASOMES; INTERLEUKIN-1; INTERLEUKIN-18; RHEUMATIC DISEASES;

EID: 84879885166     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.61     Document Type: Review

References (94)

1. Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of pro IL-1β. Mol. Cell 10, 417-426 (2002). (Pubitemid 35007355)
2. Franchi, L., Munoz-Planillo, R. & Nunez, G. Sensing and reacting to microbes through the inflammasomes. Nature Immunol. 13, 325-332 (2012).
3. Gross, O., Thomas, C. J., Guarda, G. & Tschopp, J. The inflammasome: an integrated view. Immunol. Rev. 243, 136-151 (2011).
4. Strowig, T, Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012).
5. Murakami, T. et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl Acad. Sci. USA 109, 11282-11287 (2012).
6. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401-414 (2012).
7. Bauernfeind, F. G. et al. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787-791 (2009).
8. Willingham, S. B. et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and-independent pathways. J. Immunol. 183, 2008-2015 (2009).
9. Miller, A. F Superoxide dismutases: ancient enzymes and new insights. FEBS Lett. 586, 585-595 (2012).
10. Menu, P. et al. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway Cell Death Dis. 3, e261 (2012).
11. Naik, E. & Dixit, V M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J. Exp. Med. 208, 417-420 (2011).
12. Rubartelli, A., Gattorno, M., Netea, M. G. & Dinarello, C. A. Interplay between redox status and inflammasome activation. Trends Immunol. 32, 559-566 (2011).
13. Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221-225 (2011).
14. Jin, C. et al. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy Proc. Natl Acad. Sci. USA 108, 14867-14872 (2011).
15. Pazar, B. et al. Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro. J. Immunol. 186, 2495-2502 (2011).
16. Cassel, S. L. et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl Acad. Sci. USA 105, 9035-9040 (2008).
17. Dostert, C. et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008). (Pubitemid 351928351)
18. Bylund, J. et al. Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-κB. Eur. J. Immunol. 37, 1087-1096 (2007). (Pubitemid 46925344)
19. van de Veerdonk, F. L. et al. Reactive oxygen species-independent activation of the IL-1β inflammasome in cells from patients with chronic granulomatous disease. Proc. Natl Acad. Sci. USA 107, 3030-3033 (2010).
20. Meissner, F., Molawi, K. & Zychlinsky, A. Superoxide dismutase 1 regulates caspase-1 and endotoxic shock. Nat Immunol. 9, 866-872 (2008).
21. Zhou, R., Tardivel, A., Thorens, B., Choi, I. & Tschopp, J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 11, 136-140 (2010).
22. Pelegrin, P., Barroso-Gutierrez, C. & Surprenant, A. P2X7 receptor differentially couples to distinct release pathways for IL-1β in mouse macrophage. J. Immunol. 180, 7147-7157 (2008).
23. Kanneganti, T. D. et al. Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of Toll-like receptor signaling. Immunity 26, 433-443 (2007).
24. Petrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583-1589 (2007). (Pubitemid 47278844)
25. Di Virgilio, F. Liaisons dangereuses: P2X7 and the inflammasome. Trends Pharmacol. Sci. 28, 465-472 (2007).
26. 2+ and c AMP. Nature 492, 123-127 (2012).
27. 2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nat Commun. 3, 1329 (2012).
28. Shenoy, A. R. et al. GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science 336, 481-485 (2012).
29. Lu, B. et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488, 670-674 (2012).
30. Lachmann, H. J. et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360, 2416-2425 (2009).
31. Hawkins, P. N., Lachmann, H. J., Aganna, E. & Mc Dermott, M. F. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50, 607-612 (2004). (Pubitemid 38198844)
32. Aksentijevich, I. et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum. 56, 1273-1285 (2007). (Pubitemid 46608652)
33. Tassi, S. et al. Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1β secretion. Proc. Natl Acad. Sci. USA 107, 9789-9794 (2010).
34. Hawkins, P. N., Lachmann, H. J. & Mc Dermott, M. F Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348, 2583-2584 (2003).
35. Alexander, T. et al. Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist. Ann. Rheum. Dis. 64, 1245-1246 (2005). (Pubitemid 41113374)
36. Hoffman, H. M. et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58, 2443-2452 (2008).
37. Hoffman, H. M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779-1785 (2004). (Pubitemid 39488063)
38. Agostini, L. et al. NALP3 forms an L-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319-325 (2004). (Pubitemid 38388233)
39. Brydges, S. D. et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30, 875-887 (2009).
40. Meng, G., Zhang, F., Fuss, I., Kitani, A. & Strober, W. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30, 860-874 (2009).
41. Bonar, S. L. et al. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLo S ONE 7, e35979 (2012).
42. Tanaka, N. et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum. 63, 3625-3632 (2011).
43. Ter Haar, N. et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2011-201268.
44. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237-241 (2006). (Pubitemid 43372104)
45. So, A., De Smedt, T., Revaz, S. & Tschopp, J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9, R28 (2007).
46. So, A., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62, 3064-3076 (2010).
47. Terkeltaub, R. et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 68, 1613-1617 (2009).
48. Schumacher, H. R. Jr et al. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res. 64, 1462-1470 (2012).
49. Schlesinger, N. et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann. Rheum. Dis. 70, 1264-1271 (2011).
50. Announ, N., Palmer, G., Guerne, P. A. & Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 76, 424-426 (2009).
51. Zufferey, P. & So, A. A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder. Ann. Rheum. Dis. 72, 465-467 (2013).
52. Pascual, E., Batlle-Gualda, E., Martinez, A., Rosas, J. & Vela, P. Synovial fluid analysis for diagnosis of intercritical gout. Ann. Intern. Med. 131, 756-759 (1999). (Pubitemid 29531985)
53. Joosten, L. A. et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62, 3237-3248 (2010).
54. Zhang, Y. et al. Purine-rich foods intake and recurrent gout attacks. Ann. Rheum. Dis. 71, 1448-1453 (2012).
55. Choi, H. K., Atkinson, K., Karlson, E. W., Willett, W. & Curhan, G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363, 1277-1281 (2004). (Pubitemid 38496489)
56. Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117, 3720-3732 (2011).
57. Fontalba, A. et al. Deficiency of the NF-κB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity. J. Immunol. 179, 4867-4873 (2007).
58. Kastbom, A. et al. Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project). Rheumatology 47, 415-417 (2008).
59. Kastbom, A., Johansson, M., Verma, D., Soderkvist, P. & Rantapaa-Dahlqvist, S. CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis. Ann. Rheum. Dis. 69, 723-726 (2010).
60. Ben Hamad, M. et al. Association study of CARD8 (p.C10X) and NLRP3 (p.Q705K) variants with rheumatoid arthritis in French and Tunisian populations. Int. J. Immunogenet 39, 131-136 (2012).
61. Blomgran, R. et al. Common genetic variations in the NALP3 inflammasome are associated with delayed apoptosis of human neutrophils. PLo S ONE 7, e31326 (2012).
62. Verma, D. et al. The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production. PLo S ONE 7, e34977 (2012).
63. Kolly, L. et al. Inflammatory role of ASC in antigen-induced arthritis is independent of caspase-1, NALP-3, and IPAF. J. Immunol. 183, 4003-4012 (2009).
64. Ippagunta, S. K. et al. Inflammasome-independent role of apoptosis-associated speck-like protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis. J. Biol. Chem. 285, 12454-12462 (2010).
65. Yamazaki, H. et al. ASC plays a role in the priming phase of the immune response to type II collagen in collagen-induced arthritis. Rheumatol. Int. 32, 1625-1632 (2012).
66. Hasegawa, M. et al. ASC-mediated NF-κB activation leading to interleukin-8 production requires caspase-8 and is inhibited by CLARP. J. Biol. Chem. 280, 15122-15130 (2005). (Pubitemid 40562866)
67. Hasegawa, M. et al. Mechanism and repertoire of ASC-mediated gene expression. J. Immunol. 182, 7655-7662 (2009).
68. Joosten, L. A. et al. Inflammatory arthritis in caspase 1 gene-deficient mice: Contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1β. Arthritis Rheum. 60, 3651-3662 (2009).
69. Guma, M. et al. Caspase 1-independent activation of interleukin-1β in neutrophil-predominant inflammation. Arthritis Rheum. 60, 3642-3650 (2009).
70. Kolly, L. et al. Expression and function of the NALP3 inflammasome in rheumatoid synovium. Immunology 129, 178-185 (2010).
71. Rosengren, S., Hoffman, H. M., Bugbee, W. & Boyle, D. L. Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium. Ann. Rheum. Dis. 64, 708-714 (2005) (Pubitemid 40559297)
72. van den Berg, W. B. Arguments for interleukin 1 as a target in chronic arthritis. Ann. Rheum. Dis. 59 (Suppl. 1), i81-i84 (2000).
73. Fuerst, M. et al. Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum. 60, 2694-2703 (2009).
74. Bougault, C. et al. Stress-induced cartilage degradation does not depend on NLRP3 inflammasome in osteoarthritis. Arthritis Rheum. 64, 3972-3981 (2012).
75. Said-Sadier, N., Padilla, E., Langsley, G. & Ojcius, D. M. Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLo S ONE 5, e10008 (2010).
76. Hise, A. G. et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans. Cell Host Microbe 5, 487-497 (2009).
77. Lamkanfi, M., Malireddi, R. K. & Kanneganti, T. D. Fungal zymosan and mannan activate the cryopyrin inflammasome. J. Biol. Chem. 284, 20574-20581 (2009).
78. Oosting, M. et al. Borrelia species induce inflammasome activation and IL-17 production through a caspase-1-dependent mechanism. Eur. J. Immunol. 41, 172-181 (2011).
79. Pascual, V., Allantaz, F., Arce, E., Punaro, M. & Banchereau, J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201, 1479-1486 (2005). (Pubitemid 40664091)
80. Naumann, L. et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann. Rheum. Dis. 69, 466-467 (2010).
81. Krause, K. et al. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy 67, 943-950 (2012).
82. Pascual, V. et al. How the study of children with rheumatic diseases identified interferon-a and interleukin-1 as novel therapeutic targets. Immunol. Rev. 223, 39-59 (2008). (Pubitemid 351986188)
83. Kone-Paut, I., Sanchez, E., Le Quellec, A., Manna, R. & Touitou, I. Autoinflammatory gene mutations in Behcet's disease. Ann. Rheum. Dis. 66, 832-834 (2007). (Pubitemid 46846709)
84. Pizzirani, C. et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology 48, 1304-1308 (2009).
85. Lachmann, H. J., Quartier, P., So, A. & Hawkins, P. N. The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum. 63, 314-324 (2011).
86. Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2011-200908.
87. Gross, O. et al. Inflammasome activators induce interleukin-1a secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 36, 388-400 (2012).
88. Narayan, S. et al. Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice. Arthritis Rheum. 63, 422-433 (2011).
89. Wannamaker, W. et al. (S)-1-(S)-2-{[1-(4-amino-3-chloro-phenyl)- methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid (2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1βand IL-18. J. Pharmacol. Exp. Ther. 321, 509-516 (2007). (Pubitemid 46624508)
90. Abdollahi-Roodsaz, S. et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118, 205-216 (2008).
91. Kovarova, M. et al. NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice. J. Immunol. 189, 2006-2016 (2012).
92. Levinsohn, J. L. et al. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLo S Pathog. 8, e1002638 (2012).
93. Saiga, H. et al. Critical role of AIM2 in Mycobacterium tuberculosis infection. Int. Immunol. 24, 637-644 (2012).
94. Pierini, R. et al. AIM2/ASC triggers caspase-8-dependent apoptosis in Francisella-infected caspase-1-deficient macrophages. Cell Death Differ. 19, 1709-1721 (2012).